人表皮生长因子受体2状态对转移性结直肠癌的预后影响
The prognostic impact of human epidermal growth factor receptor 2 status in metastatic colorectal cancer.
作者信息
Bartley Karen, Snider Jeremy, Cho-Phan Cheryl, Wang Jingru, Martin Peter, Simon Cyndy, Neuberger Edward, Starling Naureen
机构信息
Pfizer Inc, South San Francisco, CA, USA.
Flatiron Health, New York, NY, USA.
出版信息
Future Sci OA. 2025 Dec;11(1):2527482. doi: 10.1080/20565623.2025.2527482. Epub 2025 Jul 9.
AIM
This study evaluated the prognostic impact of human epidermal growth factor receptor 2 (HER2) status on real-world overall survival (rwOS) in patients with metastatic colorectal cancer (mCRC) who had not received HER2-targeted therapy.
METHODS
This retrospective cohort analysis included patients diagnosed with mCRC from a US-based deidentified clinicogenomic CRC database between January 1, 2011, and March 31, 2023. Patients were evaluated based on HER2 status (HER2+ defined as documented amplification). Patient characteristics were assessed at baseline, and rwOS was assessed from start of first-line therapy.
RESULTS
Among 7121 patients included in the study, 6948 (97.6%) had HER2- mCRC, and 173 (2.4%) had HER2+ mCRC. A higher number of HER2- patients had mutations (50.7% vs 19.1%) and microsatellite instability-high tumors (3.8% vs 0.6%) than HER2+ patients, while more HER2+ patients received first-line anti-epidermal growth factor receptor therapies (16.8% vs 8.1%). Median (95% CI) rwOS was 29.6 (28.8-30.3) months for HER2- and 30.6 (24.4-38.5) months for HER2+ (unadjusted HR [95% CI], 1.02 [0.84-1.24]; adjusted HR [95% CI], 1.17 [0.96-1.43]).
CONCLUSION
HER2 status did not appear to impact rwOS. The findings from this study do not support a prognostic role for HER2 status in mCRC.
目的
本研究评估了人表皮生长因子受体2（HER2）状态对未接受HER2靶向治疗的转移性结直肠癌（mCRC）患者真实世界总生存期（rwOS）的预后影响。
方法
这项回顾性队列分析纳入了2011年1月1日至2023年3月31日期间从美国一个匿名临床基因组结直肠癌数据库中诊断为mCRC的患者。根据HER2状态（HER2+定义为记录的扩增）对患者进行评估。在基线时评估患者特征，并从一线治疗开始评估rwOS。
结果
在纳入研究的7121例患者中，6948例（97.6%）为HER2- mCRC，173例（2.4%）为HER2+ mCRC。与HER2+患者相比，HER2-患者有更多的基因突变（50.7%对19.1%）和微卫星高度不稳定肿瘤（3.8%对0.6%），而更多的HER2+患者接受一线抗表皮生长因子受体治疗（16.8%对8.1%）。HER2-患者的中位（95%CI）rwOS为29.6（28.8 - 30.3）个月，HER2+患者为30.6（24.4 - 38.5）个月（未调整的HR [95%CI]，1.02 [0.84 - 1.24]；调整后的HR [95%CI]，1.17 [0.96 - 1.43]）。
结论
HER2状态似乎不影响rwOS。本研究结果不支持HER2状态在mCRC中的预后作用。
Zotero 插件